Initially, the KDM1A inhibitor known as INCB059872 treatment was shown to induce cell differentiation in progenitor cells in AML (Johnston et al., 2020), prostate cancer and Ewing sarcoma (Fang et al., 2019). This evidence concerns the gene KDM1A and acute myeloid leukemia.